|
1
|
No authors listed. New WHO statistics
highlight increases in blood pressure and diabetes, other
noncommunicable risk factors. Cent Eur J Public Health. 20:134–149,
149. 2012.PubMed/NCBI
|
|
2
|
Leon BM and Maddox TM: Diabetes and
cardiovascular disease: Epidemiology, biological mechanisms,
treatment recommendations and future research. World J Diabetes.
6:1246–1258. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kovacic JC, Castellano JM, Farkouh ME and
Fuster V: The relationships between cardiovascular disease and
diabetes: Focus on pathogenesis. Endocrinol Metab Clin North Am.
43:41–57. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dupré J, Behme MT and McDonald TJ:
Exendin-4 normalized postcibal glycemic excursions in type 1
diabetes. J Clin Endocrinol Metab. 89:3469–3473. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sposito AC, Berwanger O, de Carvalho LSF
and Saraiva JFK: GLP-1RAs in type 2 diabetes: Mechanisms that
underlie cardiovascular effects and overview of cardiovascular
outcome data. Cardiovasc Diabetol. 17(157)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Xia C, Goud A, D'Souza J, Dahagam C, Rao
X, Rajagopalan S and Zhong J: DPP4 inhibitors and cardiovascular
outcomes: Safety on heart failure. Heart Fail Rev. 22:299–304.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lee YS and Jun HS: Anti-diabetic actions
of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism.
63:9–19. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fava S: Glucagon-like peptide 1 and the
cardiovascular system. Curr Diabetes Rev. 10:302–310.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Knop FK, Brønden A and Vilsbøll T:
Exenatide: Pharmacokinetics, clinical use, and future directions.
Expert Opin Pharmacother. 18:555–571. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jacobsen LV, Flint A, Olsen AK and
Ingwersen SH: Liraglutide in type 2 diabetes mellitus: Clinical
pharmacokinetics and pharmacodynamics. Clin Pharmacokinet.
55:657–672. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Brønden A, Knop FK and Christensen MB:
Clinical pharmacokinetics and pharmacodynamics of albiglutide. Clin
Pharmacokinet. 56:719–731. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Scheen AJ: Dulaglutide for the treatment
of type 2 diabetes. Expert Opin Biol Ther. 17:485–496.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
McCarty D, Coleman M and Boland CL:
Lixisenatide: A new daily GLP-1 agonist for type 2 diabetes
management. Ann Pharmacother. 51:401–409. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tan X, Cao X, Zhou M, Zou P and Hu J:
Efficacy and safety of once-weekly semaglutide for the treatment of
type 2 diabetes. Expert Opin Investig Drugs. 26:1083–1089.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Davies M, Pieber TR, Hartoft-Nielsen ML,
Hansen OKH, Jabbour S and Rosenstock J: Effect of oral semaglutide
compared with placebo and subcutaneous semaglutide on glycemic
control in patients with type 2 diabetes: A randomized clinical
trial. JAMA. 318:1460–1470. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shyangdan DS, Royle P, Clar C, Sharma P,
Waugh N and Snaith A: Glucagon-like peptide analogues for type 2
diabetes mellitus. Cochrane Database Syst Rev.
10(CD006423)2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ying Y, Zhu H, Liang Z, Ma X and Li S:
GLP1 protects cardiomyocytes from palmitate-induced apoptosis via
Akt/GSK3β/β-catenin pathway. J Mol Endocrinol. 55:245–262.
2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Marso SP, Bain SC, Consoli A, Eliaschewitz
FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren
ML, et al: SUSTAIN-6 Investigators. Semaglutide and cardiovascular
outcomes in patients with type 2 diabetes. N Engl J Med.
375:1834–1844. 2016. View Article : Google Scholar
|
|
19
|
Hunter K and Hölscher C: Drugs developed
to treat diabetes, liraglutide and lixisenatide, cross the blood
brain barrier and enhance neurogenesis. BMC Neurosci.
13(33)2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Marso SP, Daniels GH, Brown-Frandsen K,
Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR,
Ravn LS, et al: LEADER Steering Committee. LEADER Trial
Investigators: Liraglutide and cardiovascular outcomes in type 2
diabetes. N Engl J Med. 375:311–322. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Margulies KB, Hernandez AF, Redfield MM,
Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS,
Felker GM, et al: NHLBI Heart Failure Clinical Research Network.
Effects of liraglutide on clinical stability among patients with
advanced heart failure and reduced ejection fraction: A randomized
clinical trial. JAMA. 316:500–508. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gerstein HC, Colhoun HM, Dagenais GR, Diaz
R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier
D, et al: REWIND Trial Investigators. Design and baseline
characteristics of participants in the Researching cardiovascular
Events with a Weekly INcretin in Diabetes (REWIND) trial on the
cardiovascular effects of dulaglutide. Diabetes Obes Metab.
20:42–49. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Holman RR, Bethel MA, Mentz RJ, Thompson
VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N,
et al: EXSCEL Study Group. Effects of once-weekly exenatide on
cardiovascular outcomes in type 2 diabetes. N Engl J Med.
377:1228–1239. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Korzh O, Krasnokutskiy S and Pankova O:
Improving the drug compliance of hypertensive patients in primary
care: importance of health education and self-management. Arch Balk
Med Union. 54:497–502. 2019. View Article : Google Scholar
|
|
25
|
Valkova MP, Veleva II, Guergueltcheva VN
and Burgov PS: Impact of vascular risk factors on cognitive decline
associated with diabetes mellitus. Arch Balk Med Union. 54:492–496.
2019. View Article : Google Scholar
|
|
26
|
Munteanu MA, Gheorghe G, Stanescu AMA,
Bratu OG and Diaconu C: What is new regarding the treatment of
dyslipidemia in the 2019 European Society of Cardiology Guidelines?
Arch Balk Med Union. 53:749–752. 2019. View Article : Google Scholar
|
|
27
|
Del Olmo-Garcia MI and Merino-Torres JF:
GLP-1 receptor agonists and cardiovascular disease in patients with
type 2 diabetes. J Diabetes Res. 2018(4020492)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Patel A, MacMahon S, Chalmers J, Neal B,
Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et
al: ADVANCE Collaborative Group. Intensive blood glucose control
and vascular outcomes in patients with type 2 diabetes. N Engl J
Med. 358:2560–2572. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
UK Prospective Diabetes Study (UKPDS)
Group. Intensive blood-glucose control with sulphonyl ureas or
insulin compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS 33). Lancet.
352:837–853. 1998.PubMed/NCBI
|
|
30
|
Abdel-Daim MM, El-Tawil OS, Bungau SG and
Atanasov AG: Applications of antioxidants in metabolic disorders
and degenerative diseases: mechanistic approach. Oxidative Med Cell
Longev 2019: ID 4179676. 2019.
|
|
31
|
Saraiva FK and Sposito AC: Cardiovascular
effects of glucagon-like peptide 1 (GLP-1) receptor agonists.
Cardiovasc Diabetol. 13(142)2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sharma A, Ambrosy AP, DeVore AD, Margulies
KB, McNulty SE, Mentz RJ, Hernandez AF, Michael Felker G, Cooper
LB, Lala A, et al: Liraglutide and weight loss among patients with
advanced heart failure and a reduced ejection fraction: Insights
from the FIGHT trial. ESC Heart Fail. 5:1035–1043. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Stoicescu M, Csepento C, Mutiu G and
Bungau S: The role of increased plasmatic renin level in the
pathogenesis of arterial hypertension in young adults. Rom J
Morphol Embryol. 52 (Suppl. 1):419–423. 2011.PubMed/NCBI
|
|
34
|
Scheen AJ: GLP-1 receptor agonists and
heart failure in diabetes. Diabetes Metab. 43 (Suppl.
1)(2S13-2S19)2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bahtiyar G, Pujals-Kury J and Sacerdote A:
Cardiovascular effects of different GLP-1 receptor agonists in
patients with type 2 diabetes. Curr Diab Rep. 18(92)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Giugliano D, Meier JJ and Esposito K:
Heart failure and type 2 diabetes: From cardiovascular outcome
trials, with hope. Diabetes Obes Metab. 21:1081–1087.
2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gaman MA, Dobrica EC, Pascu EG, Cozma MA,
Epingeac ME, Gaman AM, Pantea Stoian A, Bratu OG and Diaconu CC:
Cardiometabolic risk factors for atrial fibrillation in type 2
diabetes mellitus: Focus on hypertension, metabolic syndrome and
obesity. J Mind Med Sci. 6:157–161. 2019.
|
